Last edition
News about Global Pharma
NeuroBo Pharmaceuticals Receives FDA Clearance for Phase 1 Trial of DA-1726 in Obesity Treatment
The company is set to commence a Phase 1 clinical trial for obesity treatment in the first half of this year.
Global Pharma | 03/02/2024 | By Manvi | 515
FM Sitharaman Unveils Transformative Healthcare Measures in Interim Budget 2024
To address structural deficiencies in the healthcare system, the budget outlines plans to set up additional medical colleges by leveraging existing hospital infrastructure under various departments.
Global Pharma | 02/02/2024 | By Manvi | 554
Nippon Express Strengthens Pharmaceutical Logistics with CEIV Pharma Certification
The certification, issued by the International Air Transport Association (IATA), attests to the high quality and standards of pharmaceutical transport.
Global Pharma | 01/02/2024 | By Manvi | 700
Kite's Yescarta CAR T-Cell Therapy Gets FDA Nod for Manufacturing Process Change
In the realm of CAR T-cell therapies, where personalized treatment is created from a patient's white blood cells, the approval marks a significant advancement.
Global Pharma | 31/01/2024 | By Manvi | 618
NeoImmuneTech's NT-I7 Receives FDA ODD for Advanced Pancreatic Cancer Treatment
Pancreatic cancer is an aggressive tumor-type associated with extremely poor prognosis.
Global Pharma | 30/01/2024 | By Manvi | 575
Alcami Strengthens Market Position with Acquisition of Pacific Pharmaceutical Services
In addition to the acquisition of PPS, Alcami is strategically expanding its central North Carolina pharma storage and service footprint with the opening of a new 65,000 square foot facility co-located near the Research Triangle Park's biotech and pharma hub.
Global Pharma | 30/01/2024 | By Manvi | 512
Jubilant Pharma Plans Strategic Exit from Sofie Biosciences
The pharmaceutical giant's wholly-owned subsidiary had previously invested USD 25 million in Sofie Biosciences in November 2020, currently holding a noteworthy 25.8 percent stake in the company.
Global Pharma | 29/01/2024 | By Manvi | 260
The trial's efficacy endpoints further underscore the superiority of Lutathera, with a progression-free survival hazard ratio of 0.28 and a median progression-free survival of 22.8 months, significantly outperforming high-dose octreotide LAR.
Global Pharma | 29/01/2024 | By Manvi | 661
Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe
This first-in-class PRS inhibitor has recently received 'Orphan Drug Designation (ODD)' from the European Medicines Agency (EMA), adding to its earlier designation by the US FDA for both IPF and systemic sclerosis.
Global Pharma | 29/01/2024 | By Manvi | 469
Esaote Unveils Two New Ultrasound Systems at Arab Health: MyLabA50 and MyLabA70
MyLab™A50 and MyLab™A70 embody the concept of Agility and are engineered to perform seamlessly in diverse clinical settings. With compact footprint, battery-operated lightweight and mobile design they meet the demands of most healthcare professionals.
Global Pharma | 29/01/2024 | By Manvi | 526
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy